Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542215 · ClinicalTrials.gov registry record · Phase 2
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02542215 is a Phase 2 study that was terminated before completion, run by Sucampo Pharma Americas. The registered enrollment target is 47 participants.
The verdict
NCT02542215, a Phase 2 study, was terminated before completion, sponsored by Sucampo Pharma Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral mucositis. This study will evaluate the use of cobiprostone spray to prevent oral mucositis, when given for the duration of radiation and chemotherapy (RT/CT) standard care.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
- DRUG Standard Care - Chemotherapy
- RADIATION Standard Care - Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542215
The ClinicalTrials.gov registry entry for NCT02542215 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sucampo Pharma Americas, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02542215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542215 about?
NCT02542215 is a clinical study titled "Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy". Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral mucositis. This study will evaluate the use of cobiprostone spray to...
What is the current status of trial NCT02542215?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2015-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02542215?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG), Standard Care - Chemotherapy (DRUG), Standard Care - Radiation (RADIATION).
Who is sponsoring clinical trial NCT02542215?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.